Literature DB >> 19833320

Streptococcal upper respiratory tract infections and psychosocial stress predict future tic and obsessive-compulsive symptom severity in children and adolescents with Tourette syndrome and obsessive-compulsive disorder.

Haiqun Lin1, Kyle A Williams, Liliya Katsovich, Diane B Findley, Heidi Grantz, Paul J Lombroso, Robert A King, Debra E Bessen, Dwight Johnson, Edward L Kaplan, Angeli Landeros-Weisenberger, Heping Zhang, James F Leckman.   

Abstract

BACKGROUND: One goal of this prospective longitudinal study was to identify new group A beta-hemolytic streptococcal infections (GABHS) in children and adolescents with Tourette syndrome (TS) and/or obsessive-compulsive disorder (OCD) compared with healthy control subjects. We then examined the power of GABHS infections and measures of psychosocial stress to predict future tic, obsessive-compulsive (OC), and depressive symptom severity.
METHODS: Consecutive ratings of tic, OC, and depressive symptom severity were obtained for 45 cases and 41 matched control subjects over a 2-year period. Clinical raters were blinded to the results of laboratory tests. Laboratory personnel were blinded to case or control status and clinical ratings. Structural equation modeling for unbalanced repeated measures was used to assess the sequence of new GABHS infections and psychosocial stress and their impact on future symptom severity.
RESULTS: Increases in tic and OC symptom severity did not occur after every new GABHS infection. However, the structural equation model found that these newly diagnosed infections were predictive of modest increases in future tic and OC symptom severity but did not predict future depressive symptom severity. In addition, the inclusion of new infections in the model greatly enhanced, by a factor of three, the power of psychosocial stress in predicting future tic and OC symptom severity.
CONCLUSIONS: Our data suggest that a minority of children with TS and early-onset OCD were sensitive to antecedent GABHS infections. These infections also enhanced the predictive power of current psychosocial stress on future tic and OC symptom severity. Copyright 2010 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19833320      PMCID: PMC2843763          DOI: 10.1016/j.biopsych.2009.08.020

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  59 in total

1.  Increased antistreptococcal antibody titers and anti-basal ganglia antibodies in patients with Tourette syndrome: controlled cross-sectional study.

Authors:  Renata Rizzo; Mariangela Gulisano; Piero Pavone; Fabia Fogliani; Mary M Robertson
Journal:  J Child Neurol       Date:  2006-09       Impact factor: 1.987

2.  Association between streptococcal infection and obsessive-compulsive disorder, Tourette's syndrome, and tic disorder.

Authors:  Loren K Mell; Robert L Davis; David Owens
Journal:  Pediatrics       Date:  2005-07       Impact factor: 7.124

3.  Blood gene expression profiling of neurologic diseases: a pilot microarray study.

Authors:  Yang Tang; Donald L Gilbert; Tracy A Glauser; Andrew D Hershey; Frank R Sharp
Journal:  Arch Neurol       Date:  2005-02

4.  Antibody-mediated neuronal cell signaling in behavior and movement disorders.

Authors:  Christine A Kirvan; Susan E Swedo; Lisa A Snider; Madeleine W Cunningham
Journal:  J Neuroimmunol       Date:  2006-07-27       Impact factor: 3.478

5.  Serum autoantibodies do not differentiate PANDAS and Tourette syndrome from controls.

Authors:  Harvey S Singer; John J Hong; Dustin Y Yoon; Phillip N Williams
Journal:  Neurology       Date:  2005-10-05       Impact factor: 9.910

6.  Identification of pyruvate kinase as an antigen associated with Tourette syndrome.

Authors:  Janice W Kansy; Liliya Katsovich; Kevin S McIver; Jennifer Pick; John B Zabriskie; Paul J Lombroso; James F Leckman; James A Bibb
Journal:  J Neuroimmunol       Date:  2006-10-02       Impact factor: 3.478

7.  Antineural antibody in patients with Tourette's syndrome and their family members.

Authors:  Chin-Bin Yeh; Ching-Hsing Wu; Hui-Chu Tsung; Chia-Wei Chen; Jia-Fwu Shyu; James F Leckman
Journal:  J Biomed Sci       Date:  2005-10-09       Impact factor: 8.410

8.  Increased serum levels of interleukin-12 and tumor necrosis factor-alpha in Tourette's syndrome.

Authors:  James F Leckman; Liliya Katsovich; Ivana Kawikova; Haiqun Lin; Heping Zhang; Holger Krönig; Syed Morshed; Salina Parveen; Heidi Grantz; Paul J Lombroso; Robert A King
Journal:  Biol Psychiatry       Date:  2005-03-15       Impact factor: 13.382

9.  Neuronal surface glycolytic enzymes are autoantigen targets in post-streptococcal autoimmune CNS disease.

Authors:  Russell C Dale; Paul M Candler; Andrew J Church; Robin Wait; Jennifer M Pocock; Gavin Giovannoni
Journal:  J Neuroimmunol       Date:  2005-12-13       Impact factor: 3.478

10.  Soluble adhesion molecules in Gilles de la Tourette's syndrome.

Authors:  D Martino; A J Church; G Defazio; R C Dale; N P Quinn; M M Robertson; P Livrea; M Orth; G Giovannoni
Journal:  J Neurol Sci       Date:  2005-07-15       Impact factor: 3.181

View more
  23 in total

Review 1.  Obsessive-Compulsive Disorder: Autoimmunity and Neuroinflammation.

Authors:  Mona Gerentes; Antoine Pelissolo; Krishnamoorthy Rajagopal; Ryad Tamouza; Nora Hamdani
Journal:  Curr Psychiatry Rep       Date:  2019-08-01       Impact factor: 5.285

2.  Immunoglobulin A Dysgammaglobulinemia Is Associated with Pediatric-Onset Obsessive-Compulsive Disorder.

Authors:  Kyle Williams; Leah Shorser-Gentile; Suraj Sarvode Mothi; Noah Berman; Mark Pasternack; Daniel Geller; Jolan Walter
Journal:  J Child Adolesc Psychopharmacol       Date:  2019-03-20       Impact factor: 2.576

Review 3.  A Review and Update on Tourette Syndrome: Where Is the Field Headed?

Authors:  Aysegul Gunduz; Michael S Okun
Journal:  Curr Neurol Neurosci Rep       Date:  2016-04       Impact factor: 5.081

Review 4.  Obsessive-compulsive disorder: a review of the diagnostic criteria and possible subtypes and dimensional specifiers for DSM-V.

Authors:  James F Leckman; Damiaan Denys; H Blair Simpson; David Mataix-Cols; Eric Hollander; Sanjaya Saxena; Euripedes C Miguel; Scott L Rauch; Wayne K Goodman; Katharine A Phillips; Dan J Stein
Journal:  Depress Anxiety       Date:  2010-06       Impact factor: 6.505

5.  Association of Streptococcal Throat Infection With Mental Disorders: Testing Key Aspects of the PANDAS Hypothesis in a Nationwide Study.

Authors:  Sonja Orlovska; Claus Høstrup Vestergaard; Bodil Hammer Bech; Merete Nordentoft; Mogens Vestergaard; Michael Eriksen Benros
Journal:  JAMA Psychiatry       Date:  2017-07-01       Impact factor: 21.596

Review 6.  The implication of neuroactive steroids in Tourette's syndrome pathogenesis: A role for 5α-reductase?

Authors:  M Bortolato; R Frau; S C Godar; L J Mosher; S Paba; F Marrosu; P Devoto
Journal:  J Neuroendocrinol       Date:  2013-11       Impact factor: 3.627

7.  Investigating the biological and clinical significance of human dysbioses.

Authors:  Daniel N Frank; Wei Zhu; R Balfour Sartor; Ellen Li
Journal:  Trends Microbiol       Date:  2011-07-19       Impact factor: 17.079

Review 8.  The immunobiology of Tourette's disorder, pediatric autoimmune neuropsychiatric disorders associated with Streptococcus, and related disorders: a way forward.

Authors:  Tanya K Murphy; Roger Kurlan; James Leckman
Journal:  J Child Adolesc Psychopharmacol       Date:  2010-08       Impact factor: 2.576

9.  Comparison of clinical characteristics of pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and childhood obsessive-compulsive disorder.

Authors:  Gail A Bernstein; Andrea M Victor; Allison J Pipal; Kyle A Williams
Journal:  J Child Adolesc Psychopharmacol       Date:  2010-08       Impact factor: 2.576

Review 10.  Immune-mediated animal models of Tourette syndrome.

Authors:  Mady Hornig; W Ian Lipkin
Journal:  Neurosci Biobehav Rev       Date:  2013-01-10       Impact factor: 8.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.